# US 2024/0200031 A1 · Engineered hla molecules useful for t cell and nk cell activation and expansion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200031 A1
- Document ID: US20240200031A1
- Status: Published application
- Kind: A1
- Application number: 18/555,079
- Filed: 2022-04-12
- Published: 2024-06-20
- Earliest claimed: 2021-04-12
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Katharine C Hsu; Mohammed Kazim Panjwani
- Web page: https://patentgrep.com/patent/US20240200031A1

## CPC

- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/86: Viral vectors
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2502/99: genetically modified cells
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In some aspects, the present invention involves chimeric recombinant HLA proteins that are derived from HLA-E proteins and comprise a leader peptide from an HLA-A, HLA-B, HLA-C or HLA-G protein. In some aspects, the present invention also involves nucleic acid molecules encoding such recombinant HLA proteins, vectors comprising such nucleic acid molecules, host cells comprising such recombinant HLA proteins, and various related compositions. In some aspects, the present invention also involves methods of use of such recombinant HLA proteins, nucleic acid molecules, vectors, host cells and compositions.

## Claims

### Claim 1

A recombinant HLA protein comprising, from N-terminal to C-terminal: (a) a leader peptide from an HLA-A, HLA-B, HLA-C, or HLA-G molecule, and (b) an HLA-E protein, wherein the recombinant HLA protein does not comprise an HLA-E leader peptide.

### Claim 2 (depends on 1)

The recombinant HLA protein of claim 1, wherein there are no intervening amino acids between the leader peptide and the HLA-E protein.

### Claim 3 (depends on 1)

The recombinant HLA protein of claim 1, wherein the leader peptide comprises amino acids 3-11 of any one of SEQ ID NOs. 33-47.

### Claim 4 (depends on 1)

The recombinant HLA protein of claim 1, wherein the leader peptide comprises any one of SEQ ID NOs. 33-47.

### Claim 5 (depends on 1)

The recombinant HLA protein of claim 1, wherein the HLA-E protein comprises amino acids 22-358 of SEQ ID NO. 31 or SEQ ID NO. 32.

### Claim 6 (depends on 1)

The recombinant HLA protein of claim 1, comprising any one of SEQ ID NO. 1 to SEQ ID NO. 30.

### Claim 7 (depends on 1)

The recombinant HLA protein of claim 1, consisting of any one of SEQ ID NO. 1 to SEQ ID NO. 30.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A recombinant HLA protein produced intracellularly from a recombinant HLA protein of any of claims 1-7.

### Claim 9 (depends on 8)

The recombinant HLA protein of claim 8, wherein the protein is produced intracellularly by proteolytic removal of the leader peptide by a signal peptidase.

### Claim 10

A nucleic acid molecule encoding a recombinant HLA protein according to any of the preceding claims.

### Claim 11 (depends on 10)

The nucleic acid molecule of claim 10, wherein the nucleic acid molecule is a DNA molecule.

### Claim 12 (depends on 10)

The nucleic acid molecule of claim 10, wherein the nucleic acid molecule is an RNA molecule.

### Claim 13 (depends on 11)

The nucleic acid molecule according to claim 11, wherein the nucleic acid molecule encoding the recombinant HLA protein is operatively linked to a promoter.

### Claim 14 (depends on 13)

The nucleic acid molecule according to claim 13, wherein promoter is an EF1α promoter.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The nucleic acid molecule according to any of claims 10-14, wherein the nucleic acid molecule is codon optimized for human expression.

### Claim 16 (depends on 10, 11, 12, 13, 14, 15)

A vector comprising a nucleic acid molecule according to any of claims 10-15.

### Claim 17 (depends on 16)

The vector according to claim 16, wherein the vector is a lentiviral vector.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A host cell comprising a recombinant HLA protein according to any of claims 1-9.

### Claim 19 (depends on 10, 11, 12, 13, 14, 15, 16, 17)

A host cell comprising a nucleic acid molecule according to any of claims 10-15 or a vector according to any of claims 16-17.

### Claim 20 (depends on 18, 19)

A host cell according to claim 18 or claim 19, wherein the cell is a 721.221 cell.

### Claim 21 (depends on 18, 19)

A host cell according to claim 18 or claim 19, wherein the cell is a K562 cell.

### Claim 22 (depends on 18, 19)

A host cell according to claim 18 or claim 19, wherein the cell is a K562 c9.mbIL-21 cell.

### Claim 23 (depends on 18, 19)

A host cell according to claim 18 or claim 19, wherein the cell is a BAF3 cell.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A composition comprising a recombinant HLA protein according to any of claims 1-9, a nucleic acid molecule according to any of claims 10-15, a vector according to any of claims 16-17, or a host cell according to any of claims 18-23.

### Claim 25 (depends on 18, 19, 20, 21, 22, 23)

A method for activating or expanding T cells or NK cells, the method comprising contacting T cells or NK cells with host cells according to any of claims 18-23.

### Claim 26 (depends on 25)

The method of claim 25, wherein the T cells are CD8+ T cells.

### Claim 27 (depends on 26)

The method of claim 26, wherein the T cells are NKG2C+CD8+ T cells.

### Claim 28 (depends on 25, 26, 27)

The method of any of claims 25-27, wherein the contacting is in vivo.

### Claim 29 (depends on 25, 26, 27)

The method of any of claims 25-27, wherein the contacting is in vitro.

### Claim 30 (depends on 29)

The method of claim 29, wherein the contacting comprises culturing the host cells and the T cells or NK cells in the presence of a suitable culture medium.

### Claim 31 (depends on 30)

The method of claim 30, wherein the culture medium comprises IL-2.
